Advaxis (NASDAQ:ADXS) was downgraded by stock analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, MarketBeat reports. They presently have a $2.00 price target on the biotechnology company’s stock, down from their previous price target of $9.00. Jefferies Financial Group’s target price points to a potential upside of 18.34% from the stock’s previous close.
A number of other equities analysts also recently issued reports on ADXS. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Advaxis in a research report on Friday, June 8th. ValuEngine raised Advaxis from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Cantor Fitzgerald cut their target price on Advaxis from $19.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Advaxis presently has a consensus rating of “Buy” and an average target price of $3.33.
Shares of Advaxis opened at $1.69 on Wednesday, MarketBeat reports. Advaxis has a 12-month low of $1.51 and a 12-month high of $7.45.
Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06. The business had revenue of $2.06 million for the quarter, compared to the consensus estimate of $3.03 million. Advaxis had a negative return on equity of 168.35% and a negative net margin of 1,041.73%. equities research analysts anticipate that Advaxis will post -1.57 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its position in shares of Advaxis by 39.9% in the 4th quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 18,892 shares during the period. DAFNA Capital Management LLC increased its position in shares of Advaxis by 182.2% in the 1st quarter. DAFNA Capital Management LLC now owns 697,000 shares of the biotechnology company’s stock valued at $1,178,000 after acquiring an additional 450,000 shares during the period. Bank of Montreal Can increased its position in shares of Advaxis by 16,465.9% in the 4th quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after acquiring an additional 430,583 shares during the period. Deutsche Bank AG increased its position in shares of Advaxis by 1,200.1% in the 4th quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after acquiring an additional 431,379 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Advaxis in the 4th quarter valued at $1,398,000. 32.94% of the stock is currently owned by hedge funds and other institutional investors.
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.